Label: LUVIRA capsule

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated January 28, 2020

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Luvira is an orally administered prescription omega-3-acid dietary supplement formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and nutritional supplementation in physiologically stressful conditions for maintenance of good health is needed.

    Luvira should be administered under the supervision of a licensed medical practitioner.

    SUPPLEMENT FACTS

    Serving Size: 1 Capsule

    Servings Per Container:90

    Amount Per Serving%Daily Value

    Total Omega-3-Acid                       1220mg*

    Eicosapentaenoic acid (EPA)           465 mg

    Docosahexaenoic acid(DHA)           375 mg

    *Daily values not established

    Other Ingredients: Gelatin (bovine), glycerin, de-ionized water.

  • INDICATIONS AND USAGE

    Luvira is an orally administered prescription omega-3-acid formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and nutritional supplementation in physiologically stressful conditions for maintenance of good health is needed.

  • WARNINGS AND PRECAUTIONS:

    This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
    Luvira should only be used under the direction and supervision of a licensed medical practitioner. Use with caution in patients that may have a medical condition, are pregnant, lactating, trying to conceive, under the age of 18, or taking medications.

  • DOSAGE AND ADMINISTRATION

    The usual dose of Luvira is 3 - 4 capsules per day.
    The daily dose may be taken as a single dose of 3 - 4 capsules or 1 – 2 capsules twice daily with or without food.

  • HOW SUPPLIED

    Luvira is supplied as clear yellowish Softgel capsule dispensed in white HDPE plastic bottles of 90ct.
    69336-349-90

  • STORAGE AND HANDLING

    Store at controlled room temperature 15°-30°C (59°F-86°F). Keep in cool dry place. Call your doctor about side effects. You may report side effects to FDA at 1-800-FDA-1088. KEEP THIS OUT OF THE REACH OF CHILDREN.

    Reserved for Professional Recommendation
    All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.

    Manufactured for:
    Sterling-Knight Pharmaceuticals, LLC
    Ripley, MS 38663
    Item 34990
    Rev. 0620-1

  • PRINCIPAL DISPLAY PANEL

    LUVIRA

  • INGREDIENTS AND APPEARANCE
    LUVIRA 
    luvira capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:69336-349
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    OMEGA-3 FATTY ACIDS (UNII: 71M78END5S) (OMEGA-3 FATTY ACIDS - UNII:71M78END5S) OMEGA-3 FATTY ACIDS1220 mg
    12-HYDROXYEICOSAPENTAENOIC ACID, (12R)- (UNII: 78P2ZC128S) (12-HYDROXYEICOSAPENTAENOIC ACID, (12R)- - UNII:78P2ZC128S) 12-HYDROXYEICOSAPENTAENOIC ACID, (12R)-465 mg
    4,7,10,13,16,19-DOCOSAHEXAENOIC ACID, (4E,7E,10E,13E,16E,19E)- (UNII: ZR7NX0Z98X) (4,7,10,13,16,19-DOCOSAHEXAENOIC ACID, (4E,7E,10E,13E,16E,19E)- - UNII:ZR7NX0Z98X) 4,7,10,13,16,19-DOCOSAHEXAENOIC ACID, (4E,7E,10E,13E,16E,19E)-375 mg
    Inactive Ingredients
    Ingredient NameStrength
    GELATIN (UNII: 2G86QN327L)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    Product Characteristics
    ColoryellowScoreno score
    ShapecapsuleSize78mm
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:69336-349-9090 in 1 BOTTLE; Type 0: Not a Combination Product01/17/2020
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other01/17/2020
    Labeler - Sterling-Knight Pharmaceuticals, LLC (079556942)
    Establishment
    NameAddressID/FEIBusiness Operations
    Sterling-Knight Pharmaceuticals, LLC079556942manufacture(69336-349)